Partillion Updates
Painting a Picture of Trends at Immunology 2024
Thousands of scientists and clinicians descended on Chicago this May with the goal of advancing the field of immunology through the exchange of ideas and information with their fellow scientists. Part of the mission of the AAI is the study of immunology in the pursuit of improving therapies for human disease. This is a brief synopsis on the trends presented at Immunology 2024.
Top Trends in Immunotherapy – Festival of Biologics 2023 Recap
Learn about the top trends at Festival of Biologics EU 2023. The heated debates over multispecific antibodies, discover why understanding the secretome is crucial for manufacturing of biologics and the current challenges in single B cell profiling.
Partillion Bioscience Corporation Announces Seed Financing, Expanded Board, and New Partnership with Alloy Therapeutics
Financing will fund growth and expansion of new functional single-cell analysis and sorting product lines for drug discovery, enabled by Partillion's proprietary Nanovial technology.
Tracking Transcripts in Biologics and Cell Therapies
In an interview with Genetic Engineering & Biotechnology News Partillion Bioscience Co-Founder and Prof of Bioengineering at UCLA, Dino Di Carlo highlights how single-cell tools such as our nanovial technology play a critical role in improving cell therapies by enabling functional screening of cells.
NCI Emerging Technologies Seminar - Driving Next Generation Cancer Immunotherapeutic Design Using Partillion Technology
Partillion Co-Founder Dr. Dino Di Carlo shares how the Nanovial technology being commercialized by Partillion Bioscience, enables scalable selection of functional immune cells, driving next-generation cancer immunotherapeutic design.
New Preprint: Association of Molecular Signatures with Antibody Secretion Using SEC-seq
In a collaboration between Partillion Bioscience and Richard James Lab at Seattle Children’s Hospital, researchers explore the link between B cell secretion of IgG, surface markers, and gene expression for thousands of single cells for the first time.
A Prologue to Starting a Biotech Company During the Pandemic
Partillion Bioscience Co-Founder, Joe de Rutte, shares the backstory of the inspiration and foundational research behind Partillion.
Partillion Wins Top New Product Award at SLAS 2022
We are excited to announce that our Nanovial product was selected for the top New Product award at the Society of Laboratory Automation and Screening International Conference and Exhibition that took place in Boston, MA on February 7th, 2022.
Partillion Selected as Finalist for Multiple Awards at SLAS 2022
Partillion Bioscience has been nominated for multiple awards at the upcoming Society for Laboratory Automation and Screening annual meeting.
Partillion Co-Founder Awarded 2020 SLAS Innovation Award
The most prestigious award of the conference, the SLAS Innovation Award, was given to Joseph De Rutte, M.S., (University of California Los Angeles, CA, USA) for his scientific podium presentation, “High-Throughput Encapsulation and Selection of Cells Based on Antibody Secretion Using Lab-on-a-Particle Technology.”